Thursday, May 3, 2018

Refuge Biotechnologies Picks Up $25M

Menlo Park-based Refuge Biotechnologies, which is developing cell therapies for oncology, said on Wednesday it has raised $25M in a Series B funding round. The funding was led by 3SBio and Sequoia China, and also included Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund, plus, 3E Bioventures, WuXi Healthcare Ventures, and ShangBay Capital. More information »